Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Phipps

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2024
A mechanistic PK/PD model of AZD0171 (anti-LIF) to support Phase II dose selectionAzar Shahraz, Mark Penney, Juliana Candido, et al.
Clinical Pharmacology in Drug Development|September 12, 2022
A Consideration of Fixed Dosing Versus Body Size-Based Dosing Strategies for Chimeric Antigen Receptor T-Cell TherapiesJimmy Zhijian He, Hechuan Wang, KyoungSoo Lim, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor AlectinibPeter N Morcos, Yumi Cleary, Elena Guerini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer ImmunotherapyBenjamin Ribba, Christophe Boetsch, Tapan Nayak, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy SubjectsPeter N Morcos, Neil Parrott, Ludger Banken, et al.
Cancer Chemotherapy and Pharmacology|January 17, 2025
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancerAburough Abegesah, Do-Youn Oh, KyoungSoo Lim, et al.
Journal of Clinical Pharmacology|June 10, 2023
Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular CarcinomaKyoungSoo Lim, Aburough Abegesah, Chunling Fan, et al.
Scientific Reports|July 28, 2025
The unfolded protein response influences therapy outcome and disease progression in chronic lymphocytic leukaemiaUmair Tahir Khan, Kim Clarke, Gina Eagle, et al.
British Journal of Clinical Pharmacology|February 19, 2008
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionKuresh A Youdim, Aref Zayed, Maurice Dickins, et al.
Investigational New Drugs|August 21, 2021
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)Georgina Meneses-Lorente, Stephen Fowler, Elena Guerini, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
CPT: Pharmacometrics & Systems Pharmacology|July 23, 2024
A mechanistic PK/PD model of AZD0171 (anti-LIF) to support Phase II dose selectionAzar Shahraz, Mark Penney, Juliana Candido, et al.
Clinical Pharmacology in Drug Development|September 12, 2022
A Consideration of Fixed Dosing Versus Body Size-Based Dosing Strategies for Chimeric Antigen Receptor T-Cell TherapiesJimmy Zhijian He, Hechuan Wang, KyoungSoo Lim, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor AlectinibPeter N Morcos, Yumi Cleary, Elena Guerini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Prediction of the Optimal Dosing Regimen Using a Mathematical Model of Tumor Uptake for Immunocytokine-Based Cancer ImmunotherapyBenjamin Ribba, Christophe Boetsch, Tapan Nayak, et al.
Clinical Pharmacology in Drug Development|August 23, 2016
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy SubjectsPeter N Morcos, Neil Parrott, Ludger Banken, et al.
Cancer Chemotherapy and Pharmacology|January 17, 2025
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancerAburough Abegesah, Do-Youn Oh, KyoungSoo Lim, et al.
Journal of Clinical Pharmacology|June 10, 2023
Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular CarcinomaKyoungSoo Lim, Aburough Abegesah, Chunling Fan, et al.
Scientific Reports|July 28, 2025
The unfolded protein response influences therapy outcome and disease progression in chronic lymphocytic leukaemiaUmair Tahir Khan, Kim Clarke, Gina Eagle, et al.
British Journal of Clinical Pharmacology|February 19, 2008
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interactionKuresh A Youdim, Aref Zayed, Maurice Dickins, et al.
Investigational New Drugs|August 21, 2021
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)Georgina Meneses-Lorente, Stephen Fowler, Elena Guerini, et al.
Pageof 4